The effects of COVID‐19 on IBD prescribing and service provision in a UK tertiary centre
GastroHep2020Vol. 2(6), pp. 318–326
Citations Over TimeTop 10% of 2020 papers
Esha Sharma, Susanna Meade, Francesca D’Errico, Polychronis Pavlidis, Raphael P. Luber, Sebastian Zeki, Katie Hill, Alexa Duff, Dearbhaile O’Hanlon, Sherill Tripoli, Anna Stanton, Andra Caracostea, Sailish Honap, Rebecca Reynolds, Simon Anderson, Shuvra Ray, Joel Mawdsley, Jeremy Sanderson, Mark Samaan, Peter M. Irving
Abstract
We observed prescribing differences during COVID-19, bypassing the initiation of immunomodulators and/or anti-TNF therapy in favour of vedolizumab with a reduction in immunomodulator prescribing. We also observed a rapid reorganisation of service provision, including a shift towards telemedicine and online solutions.
Related Papers
- → Chilblain‐like lesions after BNT162b2 mRNA COVID‐19 vaccine: a case report suggesting that ‘COVID toes’ are due to the immune reaction to SARS‐CoV‐2(2021)26 cited
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → Особенности сахароснижающей фармакотерапии у пациентов с SARS-CoV-2 (COVID-19)(2021)
- → Спонтанний пневмоторакс у хворих на нову коронавірусну хворобу SARS-CoV-2 COVID-19(2022)